Coronis is a leading Israeli Investment Company specializing in the Biotechnology sector and focusing on highly select opportunities in the therapeutic, diagnostic and agro-bio space. Coronis' team, comprised of industry experts with complementary expertise from operational, finance, and management backgrounds, has invested since 2004 over $10M in seven high quality portfolio companies. As of August 2009, Coronis' portfolio valuation has doubled , representing an IRR of more than 30% per year. |
.JPG)
PROLOR Biotech, Inc. today announced initiation of a Phase II clinical trial of hGH-CTP, the company's proprietary biobetter version of human growth hormone (hGH).
.gif)
The analysis was conducted by Evogene in collaboration with NASA, the US National Aeronautics and Space Administration, and the Air Force Research Laboratory..gif)
The study demonstrates the ability of microRNAs to accurately identify four histological types of renal tumors, namely clear cell, papillary, and chromophobe renal cell carcinoma, as well as oncocytoma, a benign tumor..gif)
BiondVax Pharmaceuticals’ Multimeric-001 Universal Flu Vaccine was found to be safe and to activate both arms of the human immune system in a trial of 60 older adult participants
AOPharma completed an investment round of $2 million led by Coronis Partners, Mr. Gur Munzer owner and CEO of Care Medical Services and the Rad BioMed incubator owned by Mr. Yehuda Zisapel. 
